First FDA-cleared Alzheimer’s blood test could make diagnoses faster, more accurate
A new blood test that detects a hallmark of Alzheimer’s is poised to change the way doctors diagnose and treat the disease.
The test, the first of its kind to be cleared by the Food and Drug Administration, is for people 55 and older who already have memory problems or other signs and symptoms of Alzheimer’s.
The results show whether the brain of a person with cognitive symptoms also has amyloid plaques, clumps of toxic proteins that build up in the spaces between brain cells. The presence of plaques in a person with cognitive symptoms usually confirms an Alzheimer’s diagnosis.
“I think the blood test is going to really revolutionize the way people with Alzheimer’s are cared for and diagnosed,” says Dr. Howard Fillit, chief science officer at the Alzheimer’s Drug Discovery Foundation.
“Primary care physicians will now have access to something that can give them a quicker read” on whether a patient has Alzheimer’s, says Maria Carrillo, chief science officer of the Alzheimer’s Association.
One benefit of a readily-available blood test will be more accurate diagnoses, Fillit says, noting that currently, primary care doctors correctly diagnose patients only about 60% of the time.
“Specialty neurologists get it right like seventy, eighty percent of the time,” He says. “With the blood test, we can get it up to over 90%.”
A PET scan is the gold standard for detecting the amyloid plaques associated with Alzheimer’s. But the technology is costly, and unavailable in many communities.
Another option is to test fluid from a spinal tap, an invasive procedure that most doctors and patients tend to avoid.
There are already lab-developed blood tests that can signal the presence of amyloid. But the Lumipulse assay, made by the diagnostic company Fujirebio, is the first to receive marketing clearance from the FDA.
Having such a test is likely to mean that many more people will be diagnosed when their symptoms are still mild, and potentially treatable.
A survey from the Alzheimer’s Association found that the vast majority of older Americans would take a blood test to find out if they have the disease.
People who are diagnosed while still in the early stages of Alzheimer’s may be eligible to receive one of the two amyloid-reducing drugs now on market.
Lab-developed blood tests have been used primarily by researchers, or by specialists in large medical centers. The test cleared by the FDA is likely to attract a much broader audience.
“It’s been through rigorous evaluation, and it provides guidance for prescribers on who’s eligible and when the test should be provided,” Carrillo says.
The result should be more testing of people in rural or underserved areas.
“Blood tests have given us an opportunity to really democratize this kind of testing,” Carrillo says.
It also means that many more of the estimated 7.2 million Americans thought to be living with Alzheimer’s are likely to get a formal diagnosis.
To help health health care providers counsel these individuals, the Alzheimer’s Association is writing guidelines on how to speak to patients about the results of a blood test, what it means to live with the disease, and what the treatment options are.
The guidelines are expected this summer.
DHS memo details how National Guard troops will be used for immigration enforcement
The memo obtained by NPR says troops would be used in activities, including in "night operations and rural interdiction," as well as "guard duty and riot control" inside detention facilities.
Court fees can pile up. An effort to make a more effective system stalls after Trump administration cuts
Court fines and fees are meant to hold people accountable. But for many, they lead to debt, arrest, and a cycle that’s hard to break. A project that started in Birmingham explored aimed to make the system better. But recently, the Trump Administration cancelled an effort to expand the research.
On Japanese Breakfast’s melancholic record, Michelle Zauner might be ‘the happiest’ she’s ever been
Zauner joins us to talk about some of the themes behind For Melancholy Brunettes (& sad women).
South Korean maestro Chung will be the first Asian to head Italy’s famed La Scala
Myung-Whun Chung will be one of the first non-Italians to take the post of music director at Milan's famous opera house.
‘The Life of Chuck’ might leave you brushing away tears — or scratching your head
Mike Flanagan's new film, a maudlin mystery about a man dying of cancer, feels hobbled by its extreme faithfulness to the Stephen King novella on which its based.
RFK Jr. is shrinking the agency that works on mental illness and addiction
The Substance Abuse and Mental Health Administration has seen its staff cut by more than a third, and it's facing deep budget cuts. Progress on overdose deaths could be lost, experts warn.